Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MDXGthis companyMiMedx Group, Inc.	$3.26	20.52×	3.9×	2.39×	10.33×	13.9%	82.6%	15.3%	11.6%	18.9%	16.7%	7.3%	0.09×	-1.73×	35.83×	4.32×	0.0%	4	6.57	2	C
BSEMBioStem Technologies, Inc.	$1.16	-9.77×	1.63×	1.34×	-121.76×	-13121.0%	93.1%	-1.5%	-13.9%	-16.8%	-1.6%	10.3%	0.09×	85.09×	0×	4.12×	0.0%	2	-3.33	2	C
CELUCelularity Inc.	$0.76	-0.31×	-0.75×	1.07×	-0.81×	-1859.9%	24.4%	-230.9%	-345.4%	241.0%	-151.1%	-46.6%	-1.07×	-0.45×	-9.08×	0.15×	20.8%	3	-16.24	2	C
LCTXLineage Cell Therapeutics, Inc.	$1.03	-5.96×	8.63×	26.4×	-5.09×	-251.4%	94.2%	-149.6%	-436.5%	-142.6%	-19.7%	-5.1%	0.05×	0.56×	0×	5.2×	0.0%	3	-3.44	1	C-
ORGOOrganogenesis Holdings Inc.	$0.82	32.38×	1.51×	1.17×	9.41×	422.9%	75.6%	9.9%	6.6%	8.5%	8.5%	-3.7%	0.31×	0.53×	0×	3.62×	0.0%	2	1.23	2	C+
RCELAvita Medical Inc.	$17.69	-1.98×	-5.77×	1.34×	-3.2×	-278.6%	82.1%	-59.4%	-67.8%	291.8%	-113.0%	-34.3%	-2.77×	-0.87×	-8.5×	0.57×	0.0%	3	-9.92	2	C
Peer median	—	-1.98×	1.51×	1.34×	-3.2×	-278.6%	82.1%	-59.4%	-67.8%	8.5%	-19.7%	-5.1%	0.05×	0.53×	0×	3.62×	0.0%	3	-3.44	2	—